ArticleAlzheimer's research & therapy2019
Use of mild cognitive impairment and prodromal AD/MCI due to AD in clinical care: a European survey.
Article in Alzheimer's research & therapy, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 1 synthesis or guideline pooled it, 48 citations in OpenAlex.
- Real-World Use of Symptomatic Treatments in Early Alzheimer's Disease.Journal of Alzheimer's disease : JAD · 2023Pooled it
- Perspectives from Alzheimer's Disease Research Centers site directors on the early steps and the lasting impact.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026Article
- Evaluating dementia risk prediction in mild cognitive impairment: an early health technology assessment of the AI-Mind tool.GeroScience · 2026Article
- Estimating the Future Health and Social Care Costs of Alzheimer's Disease Dementia in the UK: Impact of Disease Modifying Therapy Efficacy, Uptake, and Care Model - A Scenario Modelling Study.International journal of geriatric psychiatry · 2026Article
- Investigating the Amyloid-Tau-Neurodegeneration Framework in Alzheimer's Disease Using Semi-Supervised Multimodal Imaging Data Fusion.medRxiv : the preprint server for health sciences · 2025Article
- The Impact of Cognitive Impairment on Cardiovascular Disease.Journal of the American College of Cardiology · 2025Review
- Independent validation and outlier analysis of EuroPOND alzheimer's disease staging model using ADNI and real-world clinical data.Alzheimer's research & therapy · 2025Article
- Knowledge, Attitudes, and Practices of General Physicians towards Mild Cognitive Impairment amidst an evolving era of Interprofessional Collaboration: Insights from a small-scale survey in India.BMC primary care · 2025Article
- The Use and Understanding of Mild Cognitive Impairment in Routine Specialist Care: A Survey Among German Memory Clinics.Geriatrics (Basel, Switzerland) · 2025Article
- Perspectives on the diagnosis and management of functional cognitive disorder: An international Delphi study.European journal of neurology · 2025Article
- Revised criteria for diagnosis and staging of Alzheimer's disease: Alzheimer's Association Workgroup.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2024Article
- Effects of workbook training using editorials and newspaper articles in adults with preclinical stage of dementia.Scientific reports · 2024Article
- Communication about diagnosis, prognosis, and prevention in the memory clinic: perspectives of European memory clinic professionals.Alzheimer's research & therapy · 2023Article
- Intelligent digital tools for screening of brain connectivity and dementia risk estimation in people affected by mild cognitive impairment: the AI-Mind clinical study protocol.Frontiers in neurorobotics · 2023Article
- Assessing and disclosing test results for 'mild cognitive impairment': the perspective of old age psychiatrists in Scotland.BMC geriatrics · 2022Article
- The Clinical Use of Alzheimer's Disease Biomarkers in Patients with Mild Cognitive Impairment: A European Alzheimer's Disease Consortium Survey.Journal of Alzheimer's disease : JAD · 2022Article
- GRK5 Deficiency Causes Mild Cognitive Impairment due to Alzheimer's Disease.Journal of Alzheimer's disease : JAD · 2022Review
- European Academy of Neurology/European Alzheimer's Disease Consortium position statement on diagnostic disclosure, biomarker counseling, and management of patients with mild cognitive impairment.European journal of neurology · 2021Article
- NIA-AA Alzheimer's Disease Framework: Clinical Characterization of Stages.Annals of neurology · 2021Article
- Anticipated Social and Healthcare Economic Burden of People with Alzheimer's Disease in Two Selected Regions of the Czech Republic.Healthcare (Basel, Switzerland) · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 10 institutions in 9 countries.
Funding
Abstract
introductionThe diagnosis of mild cognitive impairment (MCI) refers to cognitive impairment not meeting dementia criteria. A survey among members of the American Association of Neurology (AAN) showed that MCI was considered a useful diagnosis. Recently, research criteria have been proposed for the diagnosis of Alzheimer's disease (AD) in MCI based on AD biomarkers (prodromal AD/MCI due to AD). The aim of this study was to investigate the attitudes of clinicians in Europe on the clinical utility of MCI and prodromal AD/MCI due to AD criteria. We also investigated whether the prodromal AD/MCI due to AD criteria impacted management of MCI patients.
methodsAn online survey was performed in 2015 among 102 members of the European Academy of Neurology (EAN) and the European Alzheimer's Disease Consortium (EADC). Questions were asked on how often criteria were used, how they were operationalized, how they changed patient management, and what were considered advantages and limitations of MCI and prodromal AD/MCI due to AD. The questionnaire consisted of 47 questions scored on a Likert scale.
resultsAlmost all respondents (92%) used the MCI diagnosis in clinical practice. Over 80% of the EAN/EADC respondents found a MCI diagnosis useful because it helped to label the cognitive problem, involve patients in planning for the future, and start risk reduction activities. These findings were similar to those reported in the AAN survey. Research criteria for prodromal AD/MCI due to AD were used by 68% of the EAN/EADC respondents. The most common reasons to use the criteria were increased certainty of diagnosis (86%), increased possibilities to provide counseling (51%), facilitation of follow-up planning (48%), start of medical intervention (49%), and response to patients' wish for a diagnosis (41%). Over 70% of the physicians considered that a diagnosis of prodromal AD/MCI due to AD had an added value over the MCI diagnosis.
conclusionsThe diagnostic criteria of MCI and prodromal AD/MCI due to AD are commonly used among EAN/EADC members. The prodromal AD/MCI due to AD were considered clinically useful and impacted patient management and communication.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.